
Tatiana Hurtado de Mendoza, PhD, is the first author of the study and assistant project scientist at UC San Diego and Moores Cancer Center.

Andrew Lowy, MD, is the co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores Cancer Center at UC San Diego Health.
In animal models, tumor-penetrating therapy allows chemotherapy drugs to be delivered deeper inside tumor tissue, increasing effectiveness
Every 12 minutes, someone in the United States dies of pancreatic cancer, which is often diagnosed late, spreads rapidly and has a five-year survival rate at approximately 10 percent. Treatment may involve radiation, surgery and chemotherapy, though often the cancer becomes resistant to drugs.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with Sanford-Burnham-Prebys Medical Discovery Institute and Columbia University, demonstrated that a new tumor-penetrating therapy, tested in animal models, may enhance the effects of chemotherapy, reduce metastasis and increase survival.
The study, published online March 9, 2021 in Nature Communications, showed how a tumor-targeting peptide, called iRGD, can sneak inside the armor that the tumor built to protect itself and use the fibrous tissue as a highway to reach deeper inside, destroying the tumor from within.
The pancreas is a large gland located behind the stomach. It makes enzymes that aid digestion and hormones that regulate blood-sugar levels. Pancreatic ductal adenocarcinoma (PDAC) is a subtype of pancreatic cancer that is highly drug-resistant due, in part, by the hard shell-like outer layer surrounding the tumor.
“This type of tumor is made up of a dense fibrous tissue that acts as a barrier to drugs trying to get through. Many drugs can reach the vessels of the tumor, but they are not able to get deep into the tissue, making treatment less effective, and that is one reason why this type of cancer is so challenging to treat,” said Tatiana Hurtado de Mendoza, PhD, first author of the study and assistant project scientist at UC San Diego School of Medicine and Moores Cancer Center.
“Our study found that the tumor-penetrating peptide iRGD is able to use this fibrous network to deliver chemotherapy drugs deep into the tumor and be more effective.”
The research team examined the microenvironment of PDAC tumors in a mouse model. They found that after targeting the tumor blood vessels, iRGD binds to high levels of ?5 integrin, a protein produced by cells known as carcinoma-associated fibroblasts (CAFs) that produce much of the tumor’s protective fibrous cover.
“We were able to closely replicate human disease in our mouse model and found that when iRGD was injected with chemotherapy in mice with high levels of ?5 integrin, there was a significant increase in survival and a reduction in the cancer spreading to other organs in the body compared to chemotherapy alone. This could be a powerful treatment strategy to target aggressive pancreatic cancer,” said Andrew Lowy, MD, co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores Cancer Center at UC San Diego Health.
“What is also exciting about this finding is the iRGD therapy did not produce any additional side effects. This is critically important when considering treatments for patients.”
The researchers said next steps include a national human clinical trial. They estimate the trial could begin in one year.
“The knowledge gained from our study has the potential to be directly applied to patient care. We also believe that the levels of ?5 integrin within a pancreatic cancer could tell us which patients would benefit the most from iRGD-combination therapy,” said Lowy.
Original Article: Therapy Sneaks into Hard Layer of Pancreatic Cancer Tumor and Destroys it From Within
More from: University of California San Diego School of Medicine | University of California San Diego | Sanford Burnham Prebys Medical Discovery Institute | Columbia University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Pancreatic cancer
- Mayor proclaims Pancreatic Cancer Awareness Month
Mayor Suzanne Myers officially proclaimed November a. According to the American Cancer Society, pancreatic cancer accounts for about 3% of all cancers in the U.S., and they estimate 64,050 people in ...
- Tunbridge Wells lorry driver found he had pancreatic cancer after tumour in gall bladder duct
Alex Watson from Grove Hill Road in Tunbridge Wells was initially prescribed allergy creams after he went to his GP in July with severe itchiness across his body and “something funny” with his urine.
- Blood Test for Early Detection of Pancreatic Cancer
Pancreatic cancer has a poor survival rates marred by a lack of distinct symptoms and screening tools needed to detect the disease in its initial stages. "There are no early detection biomarkers for ...
- How Pancreatic Cancer Can Affect Your Digestive Health: Symptoms To Note
Pancreatic cancer can have a major effect on your digestive system, leading to stomach issues. A doctor explains the association and shares symptoms.
- Pancreatic Cancer Awareness Month: Watch Out For These Uncommon Signs Of Pancreatic Cancer
November is observed as pancreatic cancer awareness month. Learn some surprising initial signs of pancreatic cancer.
Go deeper with Google Headlines on:
Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Tumor-penetrating therapy
- Ovarian Cancer: Treatment, Procedure, Cost and Side Effects
The cancer is said to be in in its last stage or stage |V if it has spread to the liver, spleen and lungs. The course of treatment for ovarian cancer depends on the stage the cancer is in along with ...
- Opinion: CAR T-cell therapy delays jeopardize lives of Canadians with blood cancer
Try refreshing your browser, or tap here to see other videos from our team. Opinion: CAR T-cell therapy delays jeopardize lives of Canadians with blood cancer Back to video Clinical trials and real ...
- Combination Therapy Holds Promise for Brain Tumor in Children
In children with BRAF-mutated low- and high-grade gliomas, a combination treatment consisting of dabrafenib and trametinib showed a definite therapeutic effect. Gliomas are cancerous brain tumors ...
- How Vesselon Can Improve the Entire Class of Radiopharmaceuticals
McNabb demonstrated an enhancement of radiation effect and superior anti-tumor effect of the combination of microspheres, ultrasound and radiation therapy compared to single treatments of each alone.
- Cancer Treatment Holds Hope in Combating Tuberculosis
An emerging cancer therapy demonstrates exceptional effectiveness in combating tuberculosis (TB), an immensely destructive infectious illness.
Go deeper with Google Headlines on:
Tumor-penetrating therapy
[google_news title=”” keyword=”tumor-penetrating therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]